Document is current

Article History

Received: 27 June 2022

Accepted: 14 February 2023

First Online: 11 April 2023

Declarations

:

: The medical ethics review boards of the University of California, San Francisco (Approval Number: 10-00532) and the four clinical centers of the Osteoarthritis Initiative project recognized the project as Health Insurance Portability and Accountability Act (HIPAA)-compliant. Subjects have given informed consent before participating in the Osteoarthritis Initiative (OAI) project.

: Not applicable.

: DJH is the co-director of the Sydney Musculoskeletal Health Flagship. In addition, DJH is the editor of the osteoarthritis section for UpToDate and co-Editor in Chief of Osteoarthritis and Cartilage. DJH provides consulting advice on scientific advisory boards for Pfizer, Lilly, TLCBio, Novartis, Tissuegene, and Biobone. AG reported receiving funding from Pfizer, TissueGene, Novartis, Medipost, Coval, TrialSpark, and ICM (for consultation), and Boston Imaging Core Lab, LLC (as the president and stockholder). SD reported that he received funding from Toshiba Medical Systems (for consultation) and grants from GERRAF and Carestream Health (for a clinical trial study). None of the authors has any conflicting personal or financial relationships that could have influenced the results of this study. Other authors declare that they did not have any competing interests.